Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
Rhea-AI Summary
Renovaro (NASDAQ: RENB) has entered into an exclusive collaboration agreement with Amsterdam University Medical Center to develop and evaluate blood platelet RNA diagnostics. The partnership aims to advance disease detection and monitoring by leveraging Renovaro's AI/Machine Learning capabilities and Nebul's compute resources to analyze disease-specific signals from blood samples.
The four-year collaboration will focus on improving predictive performance and clinical accuracy across multiple cancer types through blood sample analysis, data integration, and deep learning model development. Both organizations will jointly manage intellectual property and plan to establish a dedicated company in the Netherlands for commercialization purposes.
Positive
- Strategic partnership with a leading medical research institution
- Access to advanced blood platelet RNA diagnostic technology
- Joint intellectual property management and commercialization rights
- Planned establishment of a dedicated company for product development
Negative
- Long development timeline with initial four-year term
- No immediate revenue generation potential
- Success dependent on clinical validation outcomes
News Market Reaction
On the day this news was published, RENB gained 3.71%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.
The collaboration will focus on assessing the clinical utility of blood platelet RNA signatures as a powerful biomarker source. This effort will leverage the unique Artificial Intelligence (“AI”)/Machine Learning (“ML”) capabilities of Renovaro as well as the newly announced compute resources provided through their agreement with Nebul, to uncover subtle disease-specific signals from blood samples and is aimed at transforming diagnostic and prognostic approaches across multiple cancer types.
Under the terms of the agreement, Renovaro and Amsterdam UMC will work together to refine and improve predictive performance, aiming for a high degree of clinical accuracy. The project will involve collection and analysis of blood samples, data integration from multiple modalities, and the development of sophisticated deep learning models.
“We are excited to partner with Amsterdam UMC, a leader in translational research, to advance this promising technology,” said David Weinstein, CEO of Renovaro. “By combining their clinical expertise with our technological capabilities, we believe we can significantly accelerate the translation of blood platelet RNA diagnostics into clinical practice.”
Both organizations have committed to jointly manage the intellectual property arising from the collaboration and plan to establish a dedicated company in the Netherlands to further develop and commercialize resulting diagnostics.
The initial term of the collaboration is four years, with the possibility of extension by mutual agreement.
About Amsterdam UMC
Amsterdam UMC is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. We believe that health care practice, research and education belong together, with each shaping and informing the other. With over 16,000 people, the two locations of Amsterdam UMC work together to provide good and accessible care. Amsterdam UMC is focused on a future where diseases can be prevented and where patients receive the best treatments. The emphasis is on the complex treatment of rare disorders.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
This press release contains statements by Renovaro Biosciences Inc. (“Renovaro”, “we”, “us”, “our” or the “Company”) that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would”, ”could”, ”project”, ”plan”, “potential”, ”designed”, “seek”, “target”, variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the “SEC”), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
FAQ
What is the purpose of Renovaro's (RENB) collaboration with Amsterdam UMC?
How long is the collaboration agreement between Renovaro (RENB) and Amsterdam UMC?
What technology will Renovaro (RENB) use in this collaboration?
How will the intellectual property be managed in the Renovaro-Amsterdam UMC partnership?
What is the potential impact of Renovaro's (RENB) blood platelet RNA diagnostics?
